The South Korean pharma industry could be in for some pleasant surprises this year as several new pipeline drugs are slated to receive approvals from the US FDA or reveal their potential through key results from global Phase III trials.
If the first revolution in the Korean pharma/biotech sector was major out-licensing deals, and the second was global biosimilar leadership, the third major stage will be the first launches
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?